Evidence map›Paper›PMID 41397961›Full record

ArticleNature communications2025

An open-source screening platform accelerates discovery of drug combinations.

William C Wright, Min Pan, Gregory A Phelps, Jonathan Low, Duane Currier, Ankita Sanjali, Marlon Trotter, Jihye Hwang, Richard H Chapple, Xueying Liu and 5 more

Abstract read
In one paragraph

Article in Nature communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

William C WrightDepartment of Computational Biology, St. Jude Children's Research Hospital, Memphis, TN, USA. charlie.wright@stjude.org.ORCID http://orcid.org/0000-0002-2274-9966
Min PanDepartment of Computational Biology, St. Jude Children's Research Hospital, Memphis, TN, USA.ORCID http://orcid.org/0000-0002-9338-8491
Gregory A PhelpsDepartment of Chemical Biology & Therapeutics, St. Jude Children's Research Hospital, Memphis, TN, USA.
Jonathan LowDepartment of Chemical Biology & Therapeutics, St. Jude Children's Research Hospital, Memphis, TN, USA.
Duane CurrierDepartment of Chemical Biology & Therapeutics, St. Jude Children's Research Hospital, Memphis, TN, USA.ORCID http://orcid.org/0000-0002-0123-0233
Ankita SanjaliDepartment of Computational Biology, St. Jude Children's Research Hospital, Memphis, TN, USA.
Marlon TrotterDepartment of Chemical Biology & Therapeutics, St. Jude Children's Research Hospital, Memphis, TN, USA.ORCID http://orcid.org/0009-0001-2011-0552
Jihye HwangDepartment of Computational Biology, St. Jude Children's Research Hospital, Memphis, TN, USA.
Richard H ChappleDepartment of Computational Biology, St. Jude Children's Research Hospital, Memphis, TN, USA.ORCID http://orcid.org/0000-0002-0375-2043
Xueying LiuDepartment of Computational Biology, St. Jude Children's Research Hospital, Memphis, TN, USA.ORCID http://orcid.org/0000-0003-0654-2591
Declan BennettDepartment of Computational Biology, St. Jude Children's Research Hospital, Memphis, TN, USA.ORCID http://orcid.org/0000-0003-2614-0362
Yinwen ZhangDepartment of Computational Biology, St. Jude Children's Research Hospital, Memphis, TN, USA.
Richard E LeeDepartment of Chemical Biology & Therapeutics, St. Jude Children's Research Hospital, Memphis, TN, USA.ORCID http://orcid.org/0000-0002-2397-0443
Taosheng ChenDepartment of Chemical Biology & Therapeutics, St. Jude Children's Research Hospital, Memphis, TN, USA.ORCID http://orcid.org/0000-0001-6420-3809
Paul GeeleherDepartment of Computational Biology, St. Jude Children's Research Hospital, Memphis, TN, USA. paul.geeleher@stjude.org.ORCID http://orcid.org/0000-0002-5128-0087

Funding

Viral Vector Technology (VVTSR)P30CA021765 · NCI · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI CHARLES ROBERTS · 1985 to 2026
$166.9M
Targeting NuoD for the treatment of H. pyloriR01AI170765 · NIAID · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI Michael LaFleur, Richard E. Lee · 2023 to 2026
$3.4M
Developing new therapeutic strategies for pediatric tumors that lack clinically actionable mutationsR01CA260060 · NCI · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI Paul Geeleher · 2021 to 2026
$3.0M
Computational tools for estimating cell-type-specific effects in bulk RNA-seq and spatial transcriptomics data, using reference single-cell RNA-seq datasetsR35GM138293 · NIGMS · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI GEELEHER, PAUL · 2020 to 2024
$2.2M
Novel computational approaches for pharmacogenomic discoveryR00HG009679 · NHGRI · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI GEELEHER, PAUL · 2019 to 2021
$739k
NCI NIH HHS P30 CA021765NCI NIH HHS R01 CA260060NHGRI NIH HHS R00 HG009679NIAID NIH HHS R01 AI170765NIGMS NIH HHS R35 GM138293U.S. Department of Health & Human Services | NIH | National Human Genome Research Institute (NHGRI) R00HG009679U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences (NIGMS) R35GM138293U.S. Department of Health & Human Services | NIH | NCI | Division of Cancer Epidemiology and Genetics, National Cancer Institute (National Cancer Institute Division of Cancer Epidemiology and Genetics) R01CA260060
6 · The paper itself

Abstract

Drug combinations are essential to modern medicine, but their discovery remains slow and inefficient as experimental complexity expands rapidly with each additional drug tested. Although modern liquid handling systems enable complex and highly customizable experimental designs, a lack of strategies integrating these technologies with combination-specific analytical methods has limited throughput. Here we introduce Combocat, an open-source and streamlined framework that combines acoustic liquid handling protocols with machine learning-based inference to achieve ultrahigh-throughput drug combination screening. Using Combocat, we generate a reference dataset of over 800 unique combinations in a dense 10 × 10 matrix format across multiple cell types, and use this to train a predictive model that accurately infers drug combination effects from sparse data, drastically reducing the number of experimental measurements required. As proof of concept, we screened 9,045 combinations in a neuroblastoma cell line-the largest number of combinations tested in a single cell line to date-achieved using minimal resources. By integrating advanced drug dispensing technologies with predictive computational modeling, Combocat provides a scalable solution to accelerate the discovery of novel drug combinations.

Indexed as

Drug DiscoveryHigh-Throughput Screening AssaysCell Line, TumorDrug CombinationsDrug Evaluation, PreclinicalHumansMachine LearningNeuroblastomaDrug Combinations

Identifiers

PMID41397961
PMCPMC12705714

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.